Clinical applications of adipose-derived stromal vascular fraction in veterinary practice

Abstract

Adipose tissue-derived stromal vascular fraction (AdSVF) comprises a heterogeneous cell population, including the multipotent mesenchymal stem cells, hematopoietic stem cells, immune cells, endothelial cells, fibroblasts, and pericytes. As such, multipotent adipose tissue-derived mesenchymal stem cells (AdMSCs), are one of the important components of AdSVF. Commonly used techniques to harvest AdSVF involve enzymatic or non-enzymatic methods. The enzymatic method is considered to be the gold standard technique due to its higher yield. The cellular components of AdSVF can be resuspended in normal saline, platelet-rich plasma, or phosphate-buffered saline to produce a ready-to-use solution. Freshly isolated AdSVF has exhibited promising osteogenic and vasculogenic capacity. AdSVF has already been proven to possess therapeutic potential for osteoarthritis management. It is also an attractive therapeutic option for enhancing wound healing. In addition, the combined use of AdSVF and platelet-rich plasma has an additive stimulatory effect in accelerating wound healing and can be considered an alternative to AdMSC treatment. It is also widely used for managing various orthopaedic conditions in clinical settings and has the potential for regenerating bone, cartilage, and tendons. Autologous AdSVF cells are used along with bone substitutes and other biological factors as an alternative to conventional bone grafting techniques owing to their promising osteogenic and vasculogenic capacity. It can also be used for treating osteonecrosis, meniscus tear, chondromalacia, and tendon injuries in veterinary practice. It has several advantages over in vitro expanded AdMSC, including precluding the need for culturing, reduced risk of cell contamination, and cost-effectiveness, making it ideal for clinical use.

Engineered three-dimensional bioactive scaffold for enhanced bone regeneration through modulating transplanted adipose derived mesenchymal stem cell and stimulating angiogenesis

“…Previous studies have shown that various growth factors in the PRP matrix can promote cell proliferation. In addition, the porous structure of the 3D printing scaffold also provides sufficient space for cell proliferation (Bai et al, 2020a;Sharun et al, 2021). The limited number and survival rate of transplanted cells has always been a challenge for stem cell therapy for bone defects (Whitely et al, 2018).…”

Stromal cell therapy in cats with feline chronic gingivostomatitis: current perspectives and future direction

“… 65 In some instances, adipose-derived SVF (adSVF) is used as a first step for obtaining high cellular yield for subsequent culture expansion of adMSCs. 66 In other instances, SVF is offered as a sole therapy. Traditionally, adSVF is obtained by the enzymatic digestion of fat.…”

Wound Healing and Skin Regeneration: Present Status and Future Directions

“…Mesenchymal stem cells (MSCs) exhibit paracrine effects, immunomodulation, and differentiation capabilities contributing to tissue repair (Bist et al 2021;Peer et al 2022;Sivanarayanan et al 2023). Encouraging results from preclinical studies have paved the way for clinical trials exploring stem cell-based therapies (Sharun et al 2020;Bist et al 2021;Peer et al 2022;Sharun et al 2022;Sivanarayanan et al 2023). However, standardization of protocols, ethical considerations, and long-term safety assessments remain crucial challenges.…”